Context: Positron emission tomography is a nuclear medicine imaging that deals with physiological function using radioisotopes. With the most PET (Positron Emission Tomography) scanners in integration with the CT scanners of late, this technology has registered phenomenal growth. The small amount of radioactive material is called Radiotracers. Objective: Like 18F- Fluro-deoxy-2-glucose has widely used. In this article, the author introduced clinical applications of PET out of 25 patients who studied hypermetabolic lesions in lymph nodes. Methods: PET imaging is coincidence imaging which is different from the other imaging technique PET image formed from multiple rings of detector crystals. Each decay positron travel in tissue annihilation reaction is going on. FDG is the most commonly used radiotracer to detect and stage various types of malignancies. Result: The field of PET/CT imaging cares for many oncology patients. PET improved localization of malignant lesions. It improved staging biopsy and therapy. Conclusion: Finally, studies to data showed 4% to 10% improvement in the overall accuracy of staging/restaging in lesions. If we use Monte Carlo simulation, OLINDA/EXM software may improve further with widely used.
References
[1]
Vaquero, J.J. and Kinahan, P. (2015) Positron Emission Tomography: Current Challenges and Opportunities for Technological Advances in Clinical and Preclinical Imaging Systems. Annual Review of Biomedical Engineering, 17, 385-414.
https://doi.org/10.1146/annurev-bioeng-071114-040723
[2]
Anand, S.S., Singh, H. and Dash, A.K. (2009) Clinical Applications of PET and PET-CT. Medical Journal Armed Forces India, 65, 353-358.
https://doi.org/10.1016/S0377-1237(09)80099-3
[3]
Blake, M.A., Slattery, J.M., Kalra, M.K., Halpern, E.F., Fischmann, A.J., Mueller, P.R. and Boland, G.W. (2006) Adrenal Lesions: Characterization with Fused PET/CT Image in Patients with Proved or Suspected Malignancy—Initial Experience. Radiology, 238, 970-977. https://doi.org/10.1148/radiol.2383042164
[4]
Schelling, M., Avril, N., Naukri, J., Kuhn, W., Romer, W., Sattler, D., Werner, M., Dose, J., Janacek, F., Grief, H. and Schweiger, M. (2000) Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer. Journal of Clinical Oncology, 18, 1689-1695.
[5]
Jerusalem, G., Beguine, Y., Fossette, M., Najjar, F., Rigor, P. and Fillet, G. (1999) Whole-Body Positron Emission Tomography Using18F-Fluorodeoxyglucose for Post-Treatment Evaluation in Hodgkin’s Disease and Non-Hodgkin’s Lymphomas Higher Diagnostic and Prognostic Value than Classical Computed Tomography Scan Imaging. Blood, 94, 429-433.
[6]
Weinrich, M., Re, D., Scheid Hauer, K., Anson, S., Diolein, M., Bischoff, S., Bohlen, H., Wolf, J., Schicchi, H., Diehl, V. and Tisch, H. (2001) Thoracic Positron Emission Tomography Using 18F-Fluorodeoxyglucose for the Evaluation of Residual Mediastinal Hodgkin Disease. Blood, 98, 2930-2934.
[7]
Rousseau, C., Devillers, A., et al. (2006) Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography. Journal of Clinical Oncology, 24, 5366-5372.
[8]
Avril, N., Sassan, S., Staffeldt, B., et al. (2005) Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients with Advanced-Stage Ovarian Cancer. Journal of Clinical Oncology, 23, 7445-7458.
[9]
Boring, C.C., Squires, T.S. and Tong, T. (1992) Cancer Statistics, 1992. CA: A Cancer Journal for Clinicians, 42, 19-38. https://doi.org/10.3322/canjclin.42.1.19
[10]
Newiger, H. (1993) Die Positronen-Emissions-Tomographie (PET)—Eine neue, diagnostische Methode. Physikalische und technische Voraussetzungen [Positron-Emission Tomography (PET)—A New Diagnostic Method. Physical and Technical Requirements]. Aktuelle Radiologie, 3, 140-143.
[11]
Rohrer, E.M., Turkington, T.G. and Coleman, R.E. (2004) Clinical Applications of PET in Oncology. Radiology, 231, 305-332.
https://doi.org/10.1148/radiol.2312021185
[12]
Libellee, S., Domain, C., Bonneau, G., Aspirin, A., Caillou, B., Lombroso, J., Segal, R., Boudin, E. and Schlumberger, M. (2006) Diagnostic and Prognostic Value of 18-Fluorodeoxyglucose Positron Emission Access Tomography in Adrenocortical Carcinoma: A Prospective Comparison with Computed Tomography. Journal of Clinical Endocrinology and Metabolism, 91, 920-925.
[13]
Stanley, K.E. (1980) Prognostic Factors for Survival in Patients with Inoperable Lung Cancer. Journal of the National Cancer Institute, 65, 25-32.
[14]
Gail, M.H., Eagan, R.T., Feld, R., et al. (1984) Prognostic Factors in Patients with Resected Stage I Non-Small Cell Lung Cancer. A Report from the Lung Cancer Study Group. Cancer, 54, 1802-1813.
https://doi.org/10.1002/1097-0142(19841101)54:9%3C1802::AID-CNCR2820540908%3E3.0.CO;2-4
[15]
Geddes, D.M. (1979) The Natural History of Lung Cancer: A Review Based on Rates of Tumor Growth. British Journal of Diseases of the Chest, 73, 1-17.
https://doi.org/10.1016/0007-0971(79)90002-0
[16]
Duallings, F.G., Lowe, V.J., Patz, E.F., Vaughn, A.L., Coleman, R.E. and Wolfe, W.G. (1995) Lung Tumor Growth Correlates with Glucose Metabolism Measured by Fluoride-18-Fluorodeoxyglucose Positron Emission Tomography. The Annals of Thoracic Surgery, 60, 1348-1352. https://doi.org/10.1016/0003-4975(95)00754-9
